Market does not understand the value proposition or FTO or cardio protection and RAC has thus far failed to PR it widely and clearly. There have been some isolated efforts (the videos of last year, some good interviews) but nothing sustained. We have an unenviable obligation to teach the whole world why FTO matters and how bisantrene cures cancer. WE know it does - but nobody else does right now.
If the company is assuming publication in journals is going to fix this, they're misjudging the seriousness of the situation.
I truly hope there's a proper PR and marketing plan in place to elevate this to mainstream.
General Comments / Chat, page-8619
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.045(3.01%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.45 | $62.74K | 42.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14110 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 666 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |